Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection

Tora Sadigova

doi:doi:10.11648/j.ajbls.20241206.11

Letter |

| Peer-Reviewed

Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection

Tora Sadigova^*

Published in American Journal of Biomedical and Life Sciences (Volume 12, Issue 6)

Received: 17 October 2024 Accepted: 7 November 2024 Published: 29 November 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.

Published in	American Journal of Biomedical and Life Sciences (Volume 12, Issue 6)
DOI	10.11648/j.ajbls.20241206.11
Page(s)	93-97
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cardiotoxicity, Anti-tumor Therapy, Cardioprotective Interventions, Cardiotoxicity Prevention, SGLTi

References

[1]	Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. SGLT2 inhibitors: Beyond glycemic control. J Clin Transl Endocrinol 2024; 35: 100335.
[2]	Osataphan N, Abdel-Qadir H, Zebrowska AM, Borowiec A. Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials. Curr Oncol Rep 2024.
[3]	Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, Andersen KR, Sumin M, Zwiener I, Hernandez AF, Butler J. Baseline characteristics of patients enrolled in the EMPACT‐MI trial. Eur J Heart Fail 2023; 25: 1708–1715.
[4]	Manhas A, Tripathi D, Thomas D, Sayed N. Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer. Curr Cardiol Rep 2024; 26: 953–971.
[5]	Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. JACC Heart Fail 2022; 10: 559–567.
[6]	Daniele AJ, Gregorietti V, Costa D, López – Fernández T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial. Cardio-Oncology 2024; 10: 58.
[7]	Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, Yu W, Abudureyimu M, Pei Z, Ren J. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci 2023; 312: 121207.
[8]	Mahmoud Refaie MM, Bayoumi AM, Mokhemer SA, Shehata S, Abd El-Hameed NM. Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity. Hum Exp Toxicol 2023; 42.
[9]	Tabowei G, Dadzie SK, Perswani P, Nawaz S, Kaur M, Moqattash M, Wei CR, Hirani S. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Preventing Heart Failure in Patients Receiving Anthracycline-Based Cancer Therapy: A Systematic Review and Meta-Analysis. Cureus 2024.
[10]	Zhao G, Wang L, Fang H, Wang L. A review regarding the article ‘The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction—A systematic review’. Curr Probl Cardiol 2024; 49: 102526.

Cite This Article

Plain Text BibTeX RIS

APA Style

Sadigova, T. (2024). Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. American Journal of Biomedical and Life Sciences, 12(6), 93-97. https://doi.org/10.11648/j.ajbls.20241206.11

Copy | Download

ACS Style

Sadigova, T. Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. Am. J. Biomed. Life Sci. 2024, 12(6), 93-97. doi: 10.11648/j.ajbls.20241206.11

Copy | Download

AMA Style

Sadigova T. Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. Am J Biomed Life Sci. 2024;12(6):93-97. doi: 10.11648/j.ajbls.20241206.11

Copy | Download

@article{10.11648/j.ajbls.20241206.11,
  author = {Tora Sadigova},
  title = {Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection
},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {12},
  number = {6},
  pages = {93-97},
  doi = {10.11648/j.ajbls.20241206.11},
  url = {https://doi.org/10.11648/j.ajbls.20241206.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20241206.11},
  abstract = {Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection

AU  - Tora Sadigova
Y1  - 2024/11/29
PY  - 2024
N1  - https://doi.org/10.11648/j.ajbls.20241206.11
DO  - 10.11648/j.ajbls.20241206.11
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 93
EP  - 97
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20241206.11
AB  - Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.

VL  - 12
IS  - 6
ER  -

Copy | Download

Author Information

Tora Sadigova

Department of Internal Medicine, Azerbaijan Medical University, Baku, Azerbaijan

Contact Email

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Sadigova, T. (2024). Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. American Journal of Biomedical and Life Sciences, 12(6), 93-97. https://doi.org/10.11648/j.ajbls.20241206.11

Copy | Download

ACS Style

Sadigova, T. Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. Am. J. Biomed. Life Sci. 2024, 12(6), 93-97. doi: 10.11648/j.ajbls.20241206.11

Copy | Download

AMA Style

Sadigova T. Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection. Am J Biomed Life Sci. 2024;12(6):93-97. doi: 10.11648/j.ajbls.20241206.11

Copy | Download

@article{10.11648/j.ajbls.20241206.11,
  author = {Tora Sadigova},
  title = {Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection
},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {12},
  number = {6},
  pages = {93-97},
  doi = {10.11648/j.ajbls.20241206.11},
  url = {https://doi.org/10.11648/j.ajbls.20241206.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20241206.11},
  abstract = {Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection

AU  - Tora Sadigova
Y1  - 2024/11/29
PY  - 2024
N1  - https://doi.org/10.11648/j.ajbls.20241206.11
DO  - 10.11648/j.ajbls.20241206.11
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 93
EP  - 97
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20241206.11
AB  - Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.

VL  - 12
IS  - 6
ER  -

Copy | Download